Press releases

Eevia Health Plc receives a 5,8 MSEK/0,55 MEUR sales order for high concentrate anthocyanin organic bilberry extract

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus.

Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its consumer products across Asia and Oceania.

The sales value of this order is c. 545 000 EUR. The product is Feno-Myrtillus® bilberry extract standardized with a minimum of 36% anthocyanins. The Feno-Myrtillus® powder is extracted from arctic bilberries. The bilberry anthocyanin is a polyphenol with great benefits to human health which is included in a range of applications in food and dietary supplements with multiple benefits for human health. The order is slightly higher than earlier expectations for repeat sales of this product and is confirmed subject to the sufficient availability of raw materials at a pre-calculated raw material price for the upcoming harvest.

"With the volatility in the raw material markets due to the war in Ukraine, which is a large supplier of bilberries, and the continued pandemic, we are pleased to see that major brand organizations put their trust in Eevia Health as a reliable and high-quality supplier of berry extracts based on Swedish and Finnish bilberries," says Anna-Maija Vanhatalo, Customer Service Manager in Eevia Health.

This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on June 27, 2022.

 

 

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967                               

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

2022-07-25

Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.

2022-07-08

Analyst Group Initiates equity research Coverage of Eevia Health Plc, ("Eevia" or "The Company").

2022-07-06
Regulatory

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus.

2022-06-27

Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.

2022-06-24
Regulatory

Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Exelity AB, Sweden will provide a credit line for Eevia of up to SEK 8 million, giving the Company increased working capital flexibility to finance its continued growth.

2022-06-21

The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 21, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:

2022-06-09

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.

2022-06-02
Regulatory

The shareholders of Eevia Health Abp, company registration number 2825194-4 in Finland, are hereby called for the Annual General Meeting (AGM) to be held on June 21st 2022.

2022-05-31
Regulatory

Eevia Health Plc's (''Eevia'' or ''the Company'') Financial Statements for 2021 together with the Auditors' report have been published today.

1
2
3
4
5